B-Type Natriuretic Peptide in Heart Failure
- 1 March 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 4 (1) , 10-20
Abstract
Chronic heart failure affects nearly 5 million people living in the United States, and the majority of economic burden is the result of hospitalizations for acute decompensated congestive heart failure. Patient history and symptom assessment, physical examination, and chest radiography remain the cornerstones of diagnosis and prognostic assessment. Evaluation of endogenous B-type natriuretic peptide (BNP) has emerged as a useful addition to standard methods for diagnosis and risk stratification of suspected congestive heart failure, and final diagnosis requires integration of BNP assays with traditional methods. BNP levels >500 pg/mL are more likely to be comfirmative of a primary diagnosis of heart failure and are also important predictors for long-term adverse prognosis; >100 pg/mL but <500 pg/mL suggests a reasonable likelihood for the diagnosis of heart failure but does require thoughtful exclusion of other potential confounders such as pulmonary disease resulting in right heart failure; and <100 indicates that heart failure is very unlikely. Positive physiological effects of BNP, including improvements in hemodynamics, suppression of neurohormonal activity, preservation of renal function, diuresis and natriuresis, and balanced arterial and venous dilatation have suggested that this peptide also may have therapeutic use in congestive heart failure. In clinical trials, treatment of patients with acute decompensated congestive heart failure with nesiritide, a recombinant form of human BNP, was shown to significantly reduce pulmonary capillary wedge pressure versus placebo plus standard care, as well as provide a significant improvement in dyspnea versus placebo. Diagnostic, prognostic, and therapeutic applications of BNP can be integrated easily with standard methods to provide physicians with a useful evaluation and treatment algorithm that may result in faster identification of patients likely to benefit from early therapy, including nesiritide, thereby leading to the potential for more favorable patient outcomes.Keywords
This publication has 47 references indexed in Scilit:
- BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular DiseasesCongestive Heart Failure, 2004
- Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importancePharmacology & Therapeutics, 2004
- B‐Type Natriuretic Peptide: The Level and the Drug—Partners in the Diagnosis and Management of Congestive Heart FailureCongestive Heart Failure, 2004
- Should B-Type Natriuretic Peptide Be Measured Routinely to Guide the Diagnosis and Management of Chronic Heart Failure?Circulation, 2003
- B-type natriuretic peptide levels: A potential novel “white count” for congestive heart failureJournal of Cardiac Failure, 2001
- Plasma N-terminal pro-brain natriuretic peptide and adrenomedullinJACC, 2001
- Natriuretic peptides in assessment of left-ventricular dysfunctionScandinavian Journal of Clinical and Laboratory Investigation, 1999
- Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunctionAmerican Heart Journal, 1998
- Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload.Journal of Clinical Investigation, 1995
- The Amino-Terminal Portion of Pro-Brain Natriuretic Peptide (Pro-BNP) Circulates in Human PlasmaBiochemical and Biophysical Research Communications, 1995